News summary

BioCardia’s heart failure cell therapy moves closer in Japan

Source: Longevity Technology • Published: 18 Nov 2026, 18:33

Summarized by Masters of Longevity from Longevity Technology.

BioCardia finished regulatory consultations to ready CardiAMP marketing in Japan.

BioCardia’s heart failure cell therapy moves closer in Japan
Key Takeaways
  • BioCardia completed regulatory consultations in Japan to prepare a filing.
  • CardiAMP is an autologous mononuclear cell therapy delivered by catheter.
  • Device-enabled targeted delivery was used to reach damaged heart tissue.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.